Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Parasitology ; 136(8): 905-18, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19523250

ABSTRACT

Changes in the cardiac beta-adrenergic system in early stages of Trypanosoma cruzi infection have been described. Here, we studied an early (135 days post-infection-p.i.) and a late stage (365 days p.i.) of the cardiac chronic form of the experimental infection (Tulahuen or SGO-Z12 strains), determining plasma epinephrine and norepinephrine levels, beta-receptor density, affinity and function, cardiac cAMP concentration and phosphodiesterase activity, cardiac contractility, and the presence of beta-receptor autoantibodies. Tulahuen-infected mice presented lower epinephrine and norepinephrine levels; lower beta-receptor affinity and density; a diminished norepinephrine response and higher cAMP levels in the early stage, and a basal contractility similar to non-infected controls in the early and augmented in the late stage. The Tulahuen strain induced autoantibodies with weak beta-receptor interaction. SGO-Z12-infected mice presented lower norepinephrine levels and epinephrine levels that diminished with the evolution of the infection; lower beta-receptor affinity and an increased density; unchanged epinephrine and norepinephrine response in the early and a diminished response in the late stage; higher cAMP levels and unchanged basal contractility. The SGO-Z12 isolate induced beta-receptor autoantibodies with strong interaction with the beta-receptors. None of the antibodies, however, acted a as beta-receptor agonist. The present results demonstrate that this system is seriously compromised in the cardiac chronic stage of T. cruzi infection.


Subject(s)
Chagas Cardiomyopathy/physiopathology , Receptors, Adrenergic, beta/metabolism , Trypanosoma cruzi , Adrenergic beta-Agonists/blood , Adrenergic beta-Agonists/pharmacology , Animals , Antibody Specificity , Autoantibodies/blood , Autoantibodies/immunology , Chagas Cardiomyopathy/blood , Chagas Cardiomyopathy/pathology , Chronic Disease , Cyclic AMP/metabolism , Epinephrine/blood , Epinephrine/pharmacology , Heart/drug effects , Heart/physiopathology , Mice , Myocardial Contraction/drug effects , Myocardium/metabolism , Myocardium/pathology , Norepinephrine/blood , Norepinephrine/pharmacology , Phosphoric Diester Hydrolases/metabolism , Receptors, Adrenergic, beta/analysis
2.
Exp Parasitol ; 120(4): 397-402, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18848545

ABSTRACT

The parasite Trypanosoma cruzi is the causative agent of Chagas disease. T. cruzi invasion and replication in cardiomyocytes induce cellular injuries and cytotoxic reactions, with the production of inflammatory cytokines and nitric oxide, both source of reactive oxygen species. The myocyte response to oxidative stress involves the progression of cellular changes primarily targeting mitochondria. We studied the cardiac mitochondrial structure and the enzymatic activity of citrate synthase and respiratory chain CI-CIV complexes, in Albino Swiss mice infected with T. cruzi, Tulahuen strain and SGO Z12 isolate, in two periods of the acute infection. Changes in the mitochondrial structure were detected in both infected groups, reaching values of 71% for Tulahuen and 88% for SGO Z12 infected mice, 30 days post infection. The citrate synthase activity was different according to the evolution of the infection and the parasite strain, but the respiratory chain alterations were similar with either strain.


Subject(s)
Chagas Disease/pathology , Citrate (si)-Synthase/metabolism , Mitochondria, Heart/metabolism , Mitochondria, Heart/pathology , Multienzyme Complexes/metabolism , Acute Disease , Animals , Disease Models, Animal , Female , Male , Mice , Mitochondria, Heart/ultrastructure , Parasitemia/pathology , Trypanosoma cruzi/classification , Trypanosoma cruzi/pathogenicity
3.
Int J Antimicrob Agents ; 23(6): 634-6, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15194137

ABSTRACT

Trypanosoma cruzi trypanothione reductase is an enzyme that has been identified as a potential target for chemotherapy. Thioridazine inhibits it and prevented cardiopathy in mice infected with T. cruzi Tulahuen strain. As not all T. cruzi strains respond to treatment in the same way, an isolate from a chronic patient (SGO Z12) was used; parasitaemias were studied along with, survival, serology, electrocardiography, histology and cardiac beta receptor function. Parasitaemia in thioridazine (80 mg/(kg day) for 3 days) treated mice was less and lasted for a shorter period (P < 0.01), there were reduced electrocardiographic and histological alterations and significantly improved survival (80% of non-treated died). Treated mice had lower receptor affinity and higher density as a compensatory mechanism, modifying the course of T. cruzi infection (SGO Z12 isolate) and preventing the consequent cardiopathy.


Subject(s)
Chagas Cardiomyopathy/prevention & control , Chagas Disease/complications , Chagas Disease/drug therapy , Thioridazine/pharmacology , Thioridazine/therapeutic use , Trypanocidal Agents/therapeutic use , Trypanosoma cruzi/drug effects , Animals , Antibodies, Protozoan/blood , Disease Models, Animal , Electrocardiography , Male , Mice , Myocardium/pathology , NADH, NADPH Oxidoreductases/antagonists & inhibitors , NADH, NADPH Oxidoreductases/drug effects , Parasitemia , Survival Analysis , Trypanocidal Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...